Unit of Virus Host-Cell Interactions, UJF-EMBL-CNRS, UMI 3265, 6 rue Jules Horowitz, Grenoble Cedex 9, France.
J Struct Biol. 2010 Oct;172(1):66-74. doi: 10.1016/j.jsb.2010.02.021. Epub 2010 Mar 4.
Expression of sufficient quantities of soluble protein for structural biology and other applications is often a very difficult task, especially when multimilligram quantities are required. In order to improve yield, solubility or crystallisability of a protein, it is common to subclone shorter genetic constructs corresponding to single- or multi-domain fragments. However, it is not always clear where domain boundaries are located, especially when working on novel targets with little or no sequence similarity to other proteins. Several methods have been described employing aspects of directed evolution to the recombinant expression of challenging proteins. These combine the construction of a random library of genetic constructs of a target with a screening or selection process to identify solubly expressing protein fragments. Here we review several datasets from the ESPRIT (Expression of Soluble Proteins by Random Incremental Truncation) technology to provide a view on its capabilities. Firstly, we demonstrate how it functions using the well-characterised NF-kappaB p50 transcription factor as a model system. Secondly, application of ESPRIT to the challenging PB2 subunit of influenza polymerase has led to several novel atomic resolution structures; here we present an overview of the screening phase of that project. Thirdly, analysis of the human kinase TBK1 is presented to show how the ESPRIT technology rapidly addresses the compatibility of challenging targets with the Escherichia coli expression system.
表达足够数量的可溶性蛋白用于结构生物学和其他应用通常是一项非常困难的任务,特别是当需要毫克级数量的蛋白时。为了提高蛋白的产量、溶解度或结晶度,可以将对应于单个或多个结构域片段的较短基因构建体进行亚克隆。然而,当处理与其他蛋白几乎没有或没有序列相似性的新靶标时,并不总是清楚结构域边界的位置。已经描述了几种利用定向进化的方法来重组表达具有挑战性的蛋白。这些方法将目标的随机基因构建体文库的构建与筛选或选择过程结合起来,以鉴定可溶表达的蛋白片段。在这里,我们回顾了 ESPRIT(随机递增截断表达可溶性蛋白)技术的几个数据集,以提供对其功能的了解。首先,我们使用经过充分表征的 NF-κB p50 转录因子作为模型系统来演示其功能。其次,将 ESPRIT 应用于流感聚合酶的具有挑战性的 PB2 亚基,已经导致了几个新的原子分辨率结构;在这里,我们介绍了该项目筛选阶段的概述。第三,分析人类激酶 TBK1,以显示 ESPRIT 技术如何快速解决具有挑战性的靶标与大肠杆菌表达系统的兼容性问题。